United States Diabetes Drugs Market Report & Forecast 2021-2027

Publisher Name :
Date: 10-Sep-2021
No. of pages: 111
Inquire Before Buying

United States Diabetes Drugs Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (M Units)

United States Diabetes Drugs Market Segment Percentages, By Type, 2020 (%)

- Insulin

- DPP-4

- GLP-1

- SGLT-2

United States Diabetes Drugs Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (M Units)

United States Diabetes Drugs Market Segment Percentages, By Application, 2020 (%)

- Type 1 Diabetes

- Type 2 Diabetes

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Diabetes Drugs revenues in United States market, 2016-2021 (Estimated), ($ millions)

Key companies Diabetes Drugs revenues share in United States market, 2020 (%)

Key companies Diabetes Drugs sales in United States market, 2016-2021 (Estimated), (M Units)

Key companies Diabetes Drugs sales share in United States market, 2020 (%)

Further, the report presents profiles of competitors in the market, key players include:

- Sanofi

- AstraZeneca

- Bayer

- Biocon

- Boehringer Ingelheim

- Dongbao Pharmaceutical

- Eli Lilly

- Ganlee

- Ginwa

- Guangzhou Baiyun Mountain

- Hisun Pharmacy

- Hua Dong

- Huadong Medicine

- Jumpcan Pharmacy

- KELUN

- Merck & Co.

- MSD

- North China Pharmaceutical Group Corporation

- Novartis

- Novo Nordisk

- Sanofi

- SHIJIAZHUANG YILING PHARMACEUTICAL

- Takeda

- Taloph

- Tianan Pharmaceutical

- Tonghua DongBao

- Wanbang Biopharmaceuticals

United States Diabetes Drugs Market Report & Forecast 2021-2027

Table of Contents
1 Introduction to Research & Analysis Reports
1.1 Diabetes Drugs Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 United States Diabetes Drugs Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year
2 United States Diabetes Drugs Overall Market Size
2.1 United States Diabetes Drugs Market Size: 2021 VS 2027
2.2 United States Diabetes Drugs Revenue, Prospects & Forecasts: 2016-2027
2.3 United States Diabetes Drugs Sales: 2016-2027
3 Company Landscape
3.1 Top Diabetes Drugs Players in United States Market
3.2 Top United States Diabetes Drugs Companies Ranked by Revenue
3.3 United States Diabetes Drugs Revenue by Companies
3.4 United States Diabetes Drugs Sales by Companies
3.5 United States Diabetes Drugs Price by Manufacturer (2016-2021)
3.6 Top 3 and Top 5 Diabetes Drugs Companies in United States Market, by Revenue in 2020
3.7 Manufacturers Diabetes Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Diabetes Drugs Players in United States Market
3.8.1 List of Tier 1 Diabetes Drugs Companies in United States
3.8.2 List of Tier 2 and Tier 3 Diabetes Drugs Companies in United States
4 Sights by Type
4.1 Overview
4.1.1 By Type - United States Diabetes Drugs Market Size Markets, 2021 & 2027
4.1.2 Insulin
4.1.3 DPP-4
4.1.4 GLP-1
4.1.5 SGLT-2
4.2 By Type - United States Diabetes Drugs Revenue & Forecasts
4.2.1 By Type - United States Diabetes Drugs Revenue, 2016-2021
4.2.2 By Type - United States Diabetes Drugs Revenue, 2022-2027
4.2.3 By Type - United States Diabetes Drugs Revenue Market Share, 2016-2027
4.3 By Type - United States Diabetes Drugs Sales & Forecasts
4.3.1 By Type - United States Diabetes Drugs Sales, 2016-2021
4.3.2 By Type - United States Diabetes Drugs Sales, 2022-2027
4.3.3 By Type - United States Diabetes Drugs Sales Market Share, 2016-2027
4.4 By Type - United States Diabetes Drugs Price (Manufacturers Selling Prices), 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - United States Diabetes Drugs Market Size, 2021 & 2027
5.1.2 Type 1 Diabetes
5.1.3 Type 2 Diabetes
5.2 By Application - United States Diabetes Drugs Revenue & Forecasts
5.2.1 By Application - United States Diabetes Drugs Revenue, 2016-2021
5.2.2 By Application - United States Diabetes Drugs Revenue, 2022-2027
5.2.3 By Application - United States Diabetes Drugs Revenue Market Share, 2016-2027
5.3 By Application - United States Diabetes Drugs Sales & Forecasts
5.3.1 By Application - United States Diabetes Drugs Sales, 2016-2021
5.3.2 By Application - United States Diabetes Drugs Sales, 2022-2027
5.3.3 By Application - United States Diabetes Drugs Sales Market Share, 2016-2027
5.4 By Application - United States Diabetes Drugs Price (Manufacturers Selling Prices), 2016-2027
6 Manufacturers & Brands Profiles
6.1 Sanofi
6.1.1 Sanofi Corporation Information
6.1.2 Sanofi Overview
6.1.3 Sanofi Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.1.4 Sanofi Diabetes Drugs Product Description
6.1.5 Sanofi Recent Developments
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Overview
6.2.3 AstraZeneca Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.2.4 AstraZeneca Diabetes Drugs Product Description
6.2.5 AstraZeneca Recent Developments
6.3 Bayer
6.3.1 Bayer Corporation Information
6.3.2 Bayer Overview
6.3.3 Bayer Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.3.4 Bayer Diabetes Drugs Product Description
6.3.5 Bayer Recent Developments
6.4 Biocon
6.4.1 Biocon Corporation Information
6.4.2 Biocon Overview
6.4.3 Biocon Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.4.4 Biocon Diabetes Drugs Product Description
6.4.5 Biocon Recent Developments
6.5 Boehringer Ingelheim
6.5.1 Boehringer Ingelheim Corporation Information
6.5.2 Boehringer Ingelheim Overview
6.5.3 Boehringer Ingelheim Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.5.4 Boehringer Ingelheim Diabetes Drugs Product Description
6.5.5 Boehringer Ingelheim Recent Developments
6.6 Dongbao Pharmaceutical
6.6.1 Dongbao Pharmaceutical Corporation Information
6.6.2 Dongbao Pharmaceutical Overview
6.6.3 Dongbao Pharmaceutical Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.6.4 Dongbao Pharmaceutical Diabetes Drugs Product Description
6.6.5 Dongbao Pharmaceutical Recent Developments
6.7 Eli Lilly
6.7.1 Eli Lilly Corporation Information
6.7.2 Eli Lilly Overview
6.7.3 Eli Lilly Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.7.4 Eli Lilly Diabetes Drugs Product Description
6.7.5 Eli Lilly Recent Developments
6.8 Ganlee
6.8.1 Ganlee Corporation Information
6.8.2 Ganlee Overview
6.8.3 Ganlee Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.8.4 Ganlee Diabetes Drugs Product Description
6.8.5 Ganlee Recent Developments
6.9 Ginwa
6.9.1 Ginwa Corporation Information
6.9.2 Ginwa Overview
6.9.3 Ginwa Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.9.4 Ginwa Diabetes Drugs Product Description
6.9.5 Ginwa Recent Developments
6.10 Guangzhou Baiyun Mountain
6.10.1 Guangzhou Baiyun Mountain Corporation Information
6.10.2 Guangzhou Baiyun Mountain Overview
6.10.3 Guangzhou Baiyun Mountain Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.10.4 Guangzhou Baiyun Mountain Diabetes Drugs Product Description
6.10.5 Guangzhou Baiyun Mountain Recent Developments
6.11 Hisun Pharmacy
6.11.1 Hisun Pharmacy Corporation Information
6.11.2 Hisun Pharmacy Overview
6.11.3 Hisun Pharmacy Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.11.4 Hisun Pharmacy Diabetes Drugs Product Description
6.11.5 Hisun Pharmacy Recent Developments
6.12 Hua Dong
6.12.1 Hua Dong Corporation Information
6.12.2 Hua Dong Overview
6.12.3 Hua Dong Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.12.4 Hua Dong Diabetes Drugs Product Description
6.12.5 Hua Dong Recent Developments
6.13 Huadong Medicine
6.13.1 Huadong Medicine Corporation Information
6.13.2 Huadong Medicine Overview
6.13.3 Huadong Medicine Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.13.4 Huadong Medicine Diabetes Drugs Product Description
6.13.5 Huadong Medicine Recent Developments
6.14 Jumpcan Pharmacy
6.14.1 Jumpcan Pharmacy Corporation Information
6.14.2 Jumpcan Pharmacy Overview
6.14.3 Jumpcan Pharmacy Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.14.4 Jumpcan Pharmacy Diabetes Drugs Product Description
6.14.5 Jumpcan Pharmacy Recent Developments
6.15 KELUN
6.15.1 KELUN Corporation Information
6.15.2 KELUN Overview
6.15.3 KELUN Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.15.4 KELUN Diabetes Drugs Product Description
6.15.5 KELUN Recent Developments
6.16 Merck & Co.
6.16.1 Merck & Co. Corporation Information
6.16.2 Merck & Co. Overview
6.16.3 Merck & Co. Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.16.4 Merck & Co. Diabetes Drugs Product Description
6.16.5 Merck & Co. Recent Developments
6.17 MSD
6.17.1 MSD Corporation Information
6.17.2 MSD Overview
6.17.3 MSD Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.17.4 MSD Diabetes Drugs Product Description
6.17.5 MSD Recent Developments
6.18 North China Pharmaceutical Group Corporation
6.18.1 North China Pharmaceutical Group Corporation Corporation Information
6.18.2 North China Pharmaceutical Group Corporation Overview
6.18.3 North China Pharmaceutical Group Corporation Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.18.4 North China Pharmaceutical Group Corporation Diabetes Drugs Product Description
6.18.5 North China Pharmaceutical Group Corporation Recent Developments
6.19 Novartis
6.19.1 Novartis Corporation Information
6.19.2 Novartis Overview
6.19.3 Novartis Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.19.4 Novartis Diabetes Drugs Product Description
6.19.5 Novartis Recent Developments
6.20 Novo Nordisk
6.20.1 Novo Nordisk Corporation Information
6.20.2 Novo Nordisk Overview
6.20.3 Novo Nordisk Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.20.4 Novo Nordisk Diabetes Drugs Product Description
6.20.5 Novo Nordisk Recent Developments
6.21 Sanofi
6.21.1 Sanofi Corporation Information
6.21.2 Sanofi Overview
6.21.3 Sanofi Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.21.4 Sanofi Diabetes Drugs Product Description
6.21.5 Sanofi Recent Developments
6.22 SHIJIAZHUANG YILING PHARMACEUTICAL
6.22.1 SHIJIAZHUANG YILING PHARMACEUTICAL Corporation Information
6.22.2 SHIJIAZHUANG YILING PHARMACEUTICAL Overview
6.22.3 SHIJIAZHUANG YILING PHARMACEUTICAL Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.22.4 SHIJIAZHUANG YILING PHARMACEUTICAL Diabetes Drugs Product Description
6.22.5 SHIJIAZHUANG YILING PHARMACEUTICAL Recent Developments
6.23 Takeda
6.23.1 Takeda Corporation Information
6.23.2 Takeda Overview
6.23.3 Takeda Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.23.4 Takeda Diabetes Drugs Product Description
6.23.5 Takeda Recent Developments
6.24 Taloph
6.24.1 Taloph Corporation Information
6.24.2 Taloph Overview
6.24.3 Taloph Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.24.4 Taloph Diabetes Drugs Product Description
6.24.5 Taloph Recent Developments
6.25 Tianan Pharmaceutical
6.25.1 Tianan Pharmaceutical Corporation Information
6.25.2 Tianan Pharmaceutical Overview
6.25.3 Tianan Pharmaceutical Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.25.4 Tianan Pharmaceutical Diabetes Drugs Product Description
6.25.5 Tianan Pharmaceutical Recent Developments
6.26 Tonghua DongBao
6.26.1 Tonghua DongBao Corporation Information
6.26.2 Tonghua DongBao Overview
6.26.3 Tonghua DongBao Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.26.4 Tonghua DongBao Diabetes Drugs Product Description
6.26.5 Tonghua DongBao Recent Developments
6.27 Wanbang Biopharmaceuticals
6.27.1 Wanbang Biopharmaceuticals Corporation Information
6.27.2 Wanbang Biopharmaceuticals Overview
6.27.3 Wanbang Biopharmaceuticals Diabetes Drugs Sales and Revenue in United States Market (2016-2021)
6.27.4 Wanbang Biopharmaceuticals Diabetes Drugs Product Description
6.27.5 Wanbang Biopharmaceuticals Recent Developments
7 United States Diabetes Drugs Production Capacity, Analysis
7.1 United States Diabetes Drugs Production Capacity, 2016-2027
7.2 Diabetes Drugs Production Capacity of Key Manufacturers in United States Market
8 Key Market Trends, Opportunity, Drivers and Restraints
8.1 Market Opportunities & Trends
8.2 Market Drivers
8.3 Market Restraints
9 Diabetes Drugs Supply Chain Analysis
9.1 Diabetes Drugs Industry Value Chain
9.2 Diabetes Drugs Upstream Market
9.3 Diabetes Drugs Downstream and Clients
9.4 Marketing Channels Analysis
9.4.1 Marketing Channels
9.4.2 Diabetes Drugs Distributors and Sales Agents in United States Market
10 Conclusion
11 Appendix
11.1 Note
11.2 Examples of Clients
11.3 Author Details
11.4 Disclaimer
List of Tables
Table 1. Key Players of Diabetes Drugs in United States Market
Table 2. Top Diabetes Drugs Players in United States Market, Ranking by Revenue (2019)
Table 3. United States Diabetes Drugs Revenue by Companies, (US$, Mn), 2016-2021
Table 4. United States Diabetes Drugs Revenue Share by Companies, 2016-2021
Table 5. United States Diabetes Drugs Sales by Companies, (M Units), 2016-2021
Table 6. United States Diabetes Drugs Sales Share by Companies, 2016-2021
Table 7. Key Manufacturers Diabetes Drugs Price (2016-2021) & (USD/Unit)
Table 8. Manufacturers Diabetes Drugs Product Type
Table 9. List of Tier 1 Diabetes Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Tier 2 and Tier 3 Diabetes Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. Major Manufacturers of Insulin
Table 12. Major Manufacturers of DPP-4
Table 13. By Type - United States Diabetes Drugs Revenue, (US$, Mn), 2021 & 2027
Table 14. By Type - United States Diabetes Drugs Revenue (US$, Mn), 2016-2021
Table 15. By Type - United States Diabetes Drugs Revenue (US$, Mn), 2022-2027
Table 16. By Type - United States Diabetes Drugs Sales (M Units), 2016-2021
Table 17. By Type - United States Diabetes Drugs Sales (M Units), 2022-2027
Table 18. By Application - United States Diabetes Drugs Revenue, (US$, Mn), 2021 VS 2027
Table 19. By Application - United States Diabetes Drugs Revenue (US$, Mn), 2016-2021
Table 20. By Application - United States Diabetes Drugs Revenue (US$, Mn), 2022-2027
Table 21. By Application - United States Diabetes Drugs Sales (M Units), 2016-2021
Table 22. By Application - United States Diabetes Drugs Sales (M Units), 2022-2027
Table 23. Sanofi Corporation Information
Table 24. Sanofi Description and Major Businesses
Table 25. Sanofi Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 26. Sanofi Diabetes Drugs Product
Table 27. Sanofi Recent Developments
Table 28. AstraZeneca Corporation Information
Table 29. AstraZeneca Description and Major Businesses
Table 30. AstraZeneca Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 31. AstraZeneca Diabetes Drugs Product
Table 32. AstraZeneca Recent Developments
Table 33. Bayer Corporation Information
Table 34. Bayer Description and Major Businesses
Table 35. Bayer Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 36. Bayer Diabetes Drugs Product
Table 37. Bayer Recent Developments
Table 38. Biocon Corporation Information
Table 39. Biocon Description and Major Businesses
Table 40. Biocon Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 41. Biocon Diabetes Drugs Product
Table 42. Biocon Recent Developments
Table 43. Boehringer Ingelheim Corporation Information
Table 44. Boehringer Ingelheim Description and Major Businesses
Table 45. Boehringer Ingelheim Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 46. Boehringer Ingelheim Diabetes Drugs Product
Table 47. Boehringer Ingelheim Recent Developments
Table 48. Dongbao Pharmaceutical Corporation Information
Table 49. Dongbao Pharmaceutical Description and Major Businesses
Table 50. Dongbao Pharmaceutical Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 51. Dongbao Pharmaceutical Diabetes Drugs Product
Table 52. Dongbao Pharmaceutical Recent Developments
Table 53. Eli Lilly Corporation Information
Table 54. Eli Lilly Description and Major Businesses
Table 55. Eli Lilly Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 56. Eli Lilly Diabetes Drugs Product
Table 57. Eli Lilly Recent Developments
Table 58. Ganlee Corporation Information
Table 59. Ganlee Description and Major Businesses
Table 60. Ganlee Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 61. Ganlee Diabetes Drugs Product
Table 62. Ganlee Recent Developments
Table 63. Ginwa Corporation Information
Table 64. Ginwa Description and Major Businesses
Table 65. Ginwa Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 66. Ginwa Diabetes Drugs Product
Table 67. Ginwa Recent Developments
Table 68. Guangzhou Baiyun Mountain Corporation Information
Table 69. Guangzhou Baiyun Mountain Description and Major Businesses
Table 70. Guangzhou Baiyun Mountain Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 71. Guangzhou Baiyun Mountain Diabetes Drugs Product
Table 72. Guangzhou Baiyun Mountain Recent Developments
Table 73. Hisun Pharmacy Corporation Information
Table 74. Hisun Pharmacy Description and Major Businesses
Table 75. Hisun Pharmacy Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 76. Hisun Pharmacy Diabetes Drugs Product
Table 77. Hisun Pharmacy Recent Developments
Table 78. Hua Dong Corporation Information
Table 79. Hua Dong Description and Major Businesses
Table 80. Hua Dong Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 81. Hua Dong Diabetes Drugs Product
Table 82. Hua Dong Recent Developments
Table 83. Huadong Medicine Corporation Information
Table 84. Huadong Medicine Description and Major Businesses
Table 85. Huadong Medicine Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 86. Huadong Medicine Diabetes Drugs Product
Table 87. Huadong Medicine Recent Developments
Table 88. Jumpcan Pharmacy Corporation Information
Table 89. Jumpcan Pharmacy Description and Major Businesses
Table 90. Jumpcan Pharmacy Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 91. Jumpcan Pharmacy Diabetes Drugs Product
Table 92. Jumpcan Pharmacy Recent Developments
Table 93. KELUN Corporation Information
Table 94. KELUN Description and Major Businesses
Table 95. KELUN Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 96. KELUN Diabetes Drugs Product
Table 97. KELUN Recent Developments
Table 98. Merck & Co. Corporation Information
Table 99. Merck & Co. Description and Major Businesses
Table 100. Merck & Co. Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 101. Merck & Co. Diabetes Drugs Product
Table 102. Merck & Co. Recent Developments
Table 103. MSD Corporation Information
Table 104. MSD Description and Major Businesses
Table 105. MSD Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 106. MSD Diabetes Drugs Product
Table 107. MSD Recent Developments
Table 108. North China Pharmaceutical Group Corporation Corporation Information
Table 109. North China Pharmaceutical Group Corporation Description and Major Businesses
Table 110. North China Pharmaceutical Group Corporation Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 111. North China Pharmaceutical Group Corporation Diabetes Drugs Product
Table 112. North China Pharmaceutical Group Corporation Recent Developments
Table 113. Novartis Corporation Information
Table 114. Novartis Description and Major Businesses
Table 115. Novartis Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 116. Novartis Diabetes Drugs Product
Table 117. Novartis Recent Developments
Table 118. Novo Nordisk Corporation Information
Table 119. Novo Nordisk Description and Major Businesses
Table 120. Novo Nordisk Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 121. Novo Nordisk Diabetes Drugs Product
Table 122. Novo Nordisk Recent Developments
Table 123. Sanofi Corporation Information
Table 124. Sanofi Description and Major Businesses
Table 125. Sanofi Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 126. Sanofi Diabetes Drugs Product
Table 127. Sanofi Recent Developments
Table 128. SHIJIAZHUANG YILING PHARMACEUTICAL Corporation Information
Table 129. SHIJIAZHUANG YILING PHARMACEUTICAL Description and Major Businesses
Table 130. SHIJIAZHUANG YILING PHARMACEUTICAL Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 131. SHIJIAZHUANG YILING PHARMACEUTICAL Diabetes Drugs Product
Table 132. SHIJIAZHUANG YILING PHARMACEUTICAL Recent Developments
Table 133. Takeda Corporation Information
Table 134. Takeda Description and Major Businesses
Table 135. Takeda Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 136. Takeda Diabetes Drugs Product
Table 137. Takeda Recent Developments
Table 138. Taloph Corporation Information
Table 139. Taloph Description and Major Businesses
Table 140. Taloph Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 141. Taloph Diabetes Drugs Product
Table 142. Taloph Recent Developments
Table 143. Tianan Pharmaceutical Corporation Information
Table 144. Tianan Pharmaceutical Description and Major Businesses
Table 145. Tianan Pharmaceutical Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 146. Tianan Pharmaceutical Diabetes Drugs Product
Table 147. Tianan Pharmaceutical Recent Developments
Table 148. Tonghua DongBao Corporation Information
Table 149. Tonghua DongBao Description and Major Businesses
Table 150. Tonghua DongBao Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 151. Tonghua DongBao Diabetes Drugs Product
Table 152. Tonghua DongBao Recent Developments
Table 153. Wanbang Biopharmaceuticals Corporation Information
Table 154. Wanbang Biopharmaceuticals Description and Major Businesses
Table 155. Wanbang Biopharmaceuticals Diabetes Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 156. Wanbang Biopharmaceuticals Diabetes Drugs Product
Table 157. Wanbang Biopharmaceuticals Recent Developments
Table 158. Diabetes Drugs Production Capacity (M Units) of Key Manufacturers in United States Market, 2019-2021 (M Units)
Table 159. United States Diabetes Drugs Capacity Market Share of Key Manufacturers, 2019-2021
Table 160. Diabetes Drugs Market Opportunities & Trends in United States Market
Table 161. Diabetes Drugs Market Drivers in United States Market
Table 162. Diabetes Drugs Market Restraints in United States Market
Table 163. Diabetes Drugs Raw Materials
Table 164. Diabetes Drugs Raw Materials Suppliers in United States Market
Table 165. Typical Diabetes Drugs Downstream
Table 166. Diabetes Drugs Downstream Clients in United States Market
Table 167. Diabetes Drugs Distributors and Sales Agents in United States Market
List of Figures
Figure 1. Diabetes Drugs Product Picture
Figure 2. Diabetes Drugs Segment by Type
Figure 3. Diabetes Drugs Segment by Application
Figure 4. United States Diabetes Drugs Market Overview: 2020
Figure 5. United States Diabetes Drugs Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. United States Diabetes Drugs Revenue, 2016-2027 (US$, Mn)
Figure 7. Diabetes Drugs Sales in United States Market: 2016-2027 (M Units)
Figure 8. The Top 3 and 5 Players Market Share by Diabetes Drugs Revenue in 2020
Figure 9. Insulin Product Picture
Figure 10. DPP-4 Product Picture
Figure 11. GLP-1 Product Picture
Figure 12. SGLT-2 Product Picture
Figure 13. By Type - United States Diabetes Drugs Sales Market Share, 2016-2027
Figure 14. By Type - United States Diabetes Drugs Revenue Market Share, 2016-2027
Figure 15. By Type - United States Diabetes Drugs Price (USD/Unit), 2016-2027
Figure 16. Type 1 Diabetes
Figure 17. Type 2 Diabetes
Figure 18. By Application - United States Diabetes Drugs Sales Market Share, 2016-2027
Figure 19. By Application - United States Diabetes Drugs Revenue Market Share, 2016-2027
Figure 20. By Application - United States Diabetes Drugs Price (USD/Unit), 2016-2027
Figure 21. Sanofi Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 22. AstraZeneca Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 23. Bayer Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 24. Biocon Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 25. Boehringer Ingelheim Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 26. Dongbao Pharmaceutical Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 27. Eli Lilly Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 28. Ganlee Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 29. Ginwa Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 30. Guangzhou Baiyun Mountain Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 31. Hisun Pharmacy Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 32. Hua Dong Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 33. Huadong Medicine Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 34. Jumpcan Pharmacy Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 35. KELUN Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 36. Merck & Co. Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 37. MSD Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. North China Pharmaceutical Group Corporation Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. Novartis Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. Novo Nordisk Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. Sanofi Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. SHIJIAZHUANG YILING PHARMACEUTICAL Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 43. Takeda Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 44. Taloph Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 45. Tianan Pharmaceutical Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 46. Tonghua DongBao Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 47. Wanbang Biopharmaceuticals Diabetes Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 48. United States Diabetes Drugs Production Capacity (M Units), 2016-2027
Figure 49. Diabetes Drugs Industry Value Chain
Figure 50. Marketing Channels
  • 2021-2027 Global and Regional Glucagon Like Peptide-1 (GLP-1) Agonists Industry Status and Prospects Professional Market Research Report Standard Version
    Published: 28-Sep-2021        Price: US 3500 Onwards        Pages: 150
    The global Glucagon Like Peptide-1 (GLP-1) Agonists market was valued at 498.32 Million USD in 2020 and will grow with a CAGR of 13.25% from 2020 to 2027, based on HNY Research newly published report. The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North A......
  • 2021-2027 Global and Regional Diabetes Drugs Industry Status and Prospects Professional Market Research Report Standard Version
    Published: 22-Sep-2021        Price: US 3500 Onwards        Pages: 158
    The global Diabetes Drugs market was valued at 47750.34 Million USD in 2020 and will grow with a CAGR of 5.67% from 2020 to 2027, based on HNY Research newly published report. The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe......
  • United States Metformin Hydrochloride Market Report & Forecast 2021-2027
    Published: 21-Sep-2021        Price: US 3400 Onwards        Pages: 91
    United States Metformin Hydrochloride Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (MT) United States Metformin Hydrochloride Market Segment Percentages, By Type, 2020 (%) - Metformin HCL - Metformin DC - Others United States Metformin Hydrochloride Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (MT) United States Metformin Hydrochloride Market Segment Percentages, By Application, 2020 (%) - Metformin Hydrochloride Tab......
  • United States Liraglutide Market Report & Forecast 2021-2027
    Published: 20-Sep-2021        Price: US 3400 Onwards        Pages: 90
    United States Liraglutide Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K MT) United States Liraglutide Market Segment Percentages, By Type, 2020 (%) - Pills - Liquid United States Liraglutide Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K MT) United States Liraglutide Market Segment Percentages, By Application, 2020 (%) - Hospital - Drug Store Competitor Analysis The report also provides analy......
  • Global and United States Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Insights, Forecast to 2027
    Published: 20-Sep-2021        Price: US 3900 Onwards        Pages: 134
    Dipeptidyl Peptidase-4 (DPP-4) Inhibitors market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027. For United States ......
  • United States Insulin API Market Report & Forecast 2021-2027
    Published: 17-Sep-2021        Price: US 3400 Onwards        Pages: 91
    United States Insulin API Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (Kg) United States Insulin API Market Segment Percentages, By Type, 2020 (%) - Regular Human Insulin - Insulin Analogue United States Insulin API Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (Kg) United States Insulin API Market Segment Percentages, By Application, 2020 (%) - Fast-Acting - Premix - Long-Acting Competitor Anal......
  • United States Insulin Glargine Market Report & Forecast 2021-2027
    Published: 17-Sep-2021        Price: US 3400 Onwards        Pages: 90
    United States Insulin Glargine Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (M mL) United States Insulin Glargine Market Segment Percentages, By Type, 2020 (%) - Single Dose Vial - Pre-filled Syringe United States Insulin Glargine Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (M mL) United States Insulin Glargine Market Segment Percentages, By Application, 2020 (%) - Treat Type2 Diabetes - Treat Type1 Diabetes ......
  • United States Insulin Lispro Market Report & Forecast 2021-2027
    Published: 17-Sep-2021        Price: US 3400 Onwards        Pages: 93
    United States Insulin Lispro Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Units) United States Insulin Lispro Market Segment Percentages, By Type, 2020 (%) - Insulin aspart - Mixed insulin aspart United States Insulin Lispro Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Units) United States Insulin Lispro Market Segment Percentages, By Application, 2020 (%) - Type 1 Diabetes - Type 2 Diabetes Comp......
  • United States Insulin Market Report & Forecast 2021-2027
    Published: 17-Sep-2021        Price: US 3400 Onwards        Pages: 92
    United States Insulin Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (M Pcs) United States Insulin Market Segment Percentages, By Type, 2020 (%) - Animal Insulin - Regular Human Insulin - Insulin Analogue United States Insulin Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (M Pcs) United States Insulin Market Segment Percentages, By Application, 2020 (%) - Short Acting - Intermediate Acting - Long Acting......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs